Core Points - The company held its second extraordinary general meeting on November 28, 2025, where it approved the proposal to cancel the supervisory board and amend the Articles of Association [1][5] - Chen Hao was elected as the employee representative director of the sixth board of directors, ensuring compliance with relevant laws and regulations [2][4] Group 1: Meeting Details - The extraordinary general meeting took place on November 28, 2025, at the company's conference room in Beijing [6] - The meeting was chaired by the company's chairman, Qiu Zixin, and utilized a combination of on-site and online voting [7] Group 2: Resolutions Passed - The following proposals were approved during the meeting: 1. Cancellation of the supervisory board and amendment of the Articles of Association 2. Revision of the related party transaction management system 3. Revision of the board meeting rules 4. Revision of the shareholders' meeting rules 5. Revision of the independent director work system 6. Revision of the cumulative voting implementation details [8][9] Group 3: Legal Compliance - The meeting was witnessed by Beijing Zhonglun Law Firm, confirming that all procedures and voting results complied with legal and regulatory requirements [9]

证券日报网讯 11月28日晚间，万泰生物（603392）发布公告称，公司召开2025年第三次职工代表大 会。经与会职工代表审议，同意选举陈淏先生为公司第六届董事会职工董事。 ...

Group 1 - The total scale of public funds in China reached 36.96 trillion yuan, marking the seventh historical high this year [1] - In October, the scale of money market funds increased by over 380 billion yuan, contributing the most to the overall growth [1] - The first batch of AI ETFs saw a subscription scale exceeding 900 million yuan on the first day, nearing the upper limit of 1 billion yuan [1] Group 2 - The third quarter global DRAM sales reached 40.3 billion USD, with SK Hynix maintaining the highest market share at 34.1% [2] - The HPV vaccine market is experiencing significant challenges, with major companies reporting substantial revenue and profit declines [4] - The liquor industry is facing difficulties, with several small enterprises, including Guizhou Wuyou Liquor, encountering operational issues [5] Group 3 - Heavy Drug Holdings disclosed that 22 subsidiaries paid a total of 443.026 million yuan in back taxes [6] - Beijing Nengsi Software has restarted its IPO process after previously withdrawing its application [7] - ST Lifan's stock will be subject to delisting risk warnings due to serious violations of securities laws [14]

Group 1 - The biovaccine sector experienced a decline of 0.30% as of the market close on November 28, ranking among the top losers in concept sectors [1] - Within the biovaccine sector, notable declines were observed in Hualan Biological, Jindike, and *ST Wanfang, while 24 stocks saw price increases, with Kanghua Biological, Shenzhou Cell, and Lanxiao Technology leading the gains at 2.10%, 1.66%, and 1.66% respectively [1][2] - The biovaccine sector faced a net outflow of 499 million yuan from major funds today, with 41 stocks experiencing net outflows, and 19 stocks seeing outflows exceeding 10 million yuan [2] Group 2 - The top three stocks with the highest net outflows in the biovaccine sector were Wantai Biological (-2.18%), *ST Wanfang (-4.11%), and Jindike (-6.55%), with net outflows of 68.27 million yuan, 41.63 million yuan, and 34.53 million yuan respectively [2][3] - Conversely, the stocks with the highest net inflows included Dezhan Health, New Source, and Meihua Biological, with net inflows of 12.45 million yuan, 5.47 million yuan, and 4.02 million yuan respectively [4]

证券代码：603392 证券简称：万泰生物 公告编号：2025-061 北京万泰生物药业股份有限公司董事会 2025 年 11 月 29 日 附件：职工代表董事简历 为保证公司董事会的合规运作，公司于同日召开 2025 年第三次职工代表大 会。经与会职工代表审议，同意选举陈淏先生为公司第六届董事会职工董事（简 历详见附件）。陈淏先生将与其他 7 名现任董事以及 2025 年第二次临时股东会选 举产生的 1 名非独立董事，共同组成公司第六届董事会，任期自本次职工代表大 会审议通过之日起至公司第六届董事会任期届满之日止。 陈淏先生符合《中华人民共和国公司法》及《公司章程》规定的有关职工董 事任职资格和条件。陈淏先生当选公司职工代表董事后，公司第六届董事会中兼 任公司高级管理人员以及由职工代表担任的董事人数未超过公司董事总数的二 分之一，独立董事不少于全体董事成员的三分之一，符合相关法律法规及《公司 章程》的规定。 特此公告。 北京万泰生物药业股份有限公司 关于选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

(一)股东会召开的时间：2025 年 11 月 28 日 (二)股东会召开的地点：北京市昌平区科学园路 31 号公司会议室 证券代码：603392 证券简称：万泰生物 公告编号：2025-060 北京万泰生物药业股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 515 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 993,999,969 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 78.6148 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等 本次股东会由公司董事会召集并发布公告通知，由公司董事长邱子欣先生主 持。会议表决方式为现场和网络投票相结合，本次会议的召集与召开程序、出席 会 ...

北京市中伦律师事务所 关于北京万泰生物药业股份有限公司 2025 年第二次临时股东会的法律意见书 二〇二五年十一月 北京市中伦律师事务所 关于北京万泰生物药业股份有限公司 2025 年第二次临时股东会的法律意见书 致：北京万泰生物药业股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受北京万泰生物药业股份有限 公司（以下简称"公司"）的委托，就公司 2025 年第二次临时股东会（以下简称 "本次会议"）相关事宜，根据《中华人民共和国公司法》《中华人民共和国证券 法》《上市公司股东会规则》《上海证券交易所股票上市规则》等法律、法规和 规范性文件及现行有效的《北京万泰生物药业股份有限公司章程》（以下简称《公" 司章程》"），依法出具本法律意见书。 本法律意见书仅就本次会议的召集和召开程序、出席会议人员资格、召集人 资格、本次会议表决程序及表决结果等事项发表法律意见，并不对本次大会所审 议议案的内容以及前述议案所表述的事实或数据的真实性和准确性发表意见。本 所律师并假定：公司提交给本所律师的所有资料（包括但不限于有关人员的居民 身份证、授权委托书、营业执照、股东名册、网络投票结果等）均真实、准确、 完整；该等 ...

Core Viewpoint - Wante Bio's stock has experienced a significant decline in 2023, with a year-to-date drop of 31.73% and a recent 60-day decline of 17.40% [2] Company Overview - Wante Bio, established on April 24, 1991, and listed on April 29, 2020, is located in Changping District, Beijing. The company specializes in the research, production, and sales of in vitro diagnostic reagents, instruments, and vaccines [2] - The revenue composition of Wante Bio includes: diagnostic reagents (67.06%), vaccines (20.36%), diagnostic instruments (4.98%), agency products (4.97%), other (1.88%), and active raw materials (0.76%) [2] - As of September 30, 2025, Wante Bio had 42,000 shareholders, an increase of 9.41% from the previous period, with an average of 30,124 circulating shares per shareholder, a decrease of 8.60% [2] Financial Performance - For the period from January to September 2025, Wante Bio reported a revenue of 1.498 billion yuan, a year-on-year decrease of 23.09%, and a net profit attributable to shareholders of -173 million yuan, a year-on-year decrease of 165.04% [2] - Since its A-share listing, Wante Bio has distributed a total of 1.541 billion yuan in dividends, with 1.311 billion yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the top ten circulating shareholders of Wante Bio include Hong Kong Central Clearing Limited, which holds 12.8991 million shares (a decrease of 9.8553 million shares), and Huatai-PB CSI 300 ETF, holding 6.4061 million shares (a decrease of 318,300 shares) [3] - The China National Securities Bio-Medical Index A has entered the top ten circulating shareholders with 4.9609 million shares as a new shareholder, while E Fund CSI 300 Medical ETF has exited the list [3] Market Activity - On November 28, Wante Bio's stock price fell by 2.02%, trading at 48.10 yuan per share, with a total transaction volume of 131 million yuan and a turnover rate of 0.21%. The total market capitalization is 60.852 billion yuan [1] - In terms of capital flow, there was a net outflow of 17.3687 million yuan from main funds, with large orders showing a buy of 23.094 million yuan (17.66%) and a sell of 27.222 million yuan (20.82%) [1]

Core Viewpoint - The establishment of the Zhuji City Education Strong City Reward Fund has received a total of 142 million yuan in donations from various enterprises, with Nongfu Spring founder Zhong Shanshan donating 100 million yuan to set up the "Zhuji Middle School Zhong Ziyi Education Fund" [1][2] Group 1: Donations and Fund Establishment - Zhong Shanshan's donation of 100 million yuan is aimed at enhancing the quality of education at his hometown school, Zhuji Middle School, with funds allocated for student assistance, teacher awards, and scholarships [2] - The Zhong Ziyi Education Fund has previously donated several hundred million yuan to prestigious universities such as Tsinghua University and Peking University, focusing on higher education and research innovation [2][3] Group 2: Wealth and Philanthropy - According to the 2025 Hurun Rich List, Zhong Shanshan has a wealth of 530 billion yuan, marking his fourth time as China's richest person and setting a new record for the wealth of a Chinese billionaire [4] - Zhong's wealth primarily comes from his holdings in Nongfu Spring and Wantai Biological Pharmacy, with significant revenue growth reported for Nongfu Spring, achieving 25.622 billion yuan in revenue and a net profit of 7.622 billion yuan in the first half of 2025 [4] Group 3: Educational Initiatives - In 2025, Zhong Shanshan's educational philanthropy expanded with a 40 billion yuan donation to establish a "new type of university" in Hangzhou, recognized as one of the largest single donations in the history of private education in China [5][6] - The Hangzhou Qiantang Education Foundation, initiated by Zhong, aims to support the construction of high-level private universities and attract top scholars and talents [5][6]

Core Viewpoint - Watson Bio has received a marketing authorization for its 13-valent pneumococcal polysaccharide conjugate vaccine from the Egyptian Drug Authority, marking a significant step in its international expansion efforts [1] Group 1: Company Developments - Watson Bio's vaccine products have been exported to over 24 countries and regions, with a total export volume exceeding 63 million doses [3] - The company has successfully entered new markets including Chile and Jordan for its 13-valent pneumococcal conjugate vaccine, and has also expanded its 23-valent pneumococcal polysaccharide vaccine to Chile, Mexico, and El Salvador [2] - Watson Bio has completed a localization project in Indonesia, beginning to export raw materials to local partners [2] Group 2: Industry Trends - Multiple vaccine companies are accelerating their global strategies, with significant partnerships and contracts being established, such as Beijing Kexing's $700 million deal with Brazil [2] - The overseas sales revenue of several vaccine companies has shown substantial growth, with Chengda Bio achieving a 26.96% increase and Wantai Bio seeing a 77.51% increase in overseas sales [3] - The vaccine industry is transitioning from scale expansion to innovation-driven growth, with supply-demand imbalances and homogenized competition posing short-term challenges, but long-term growth prospects remain positive [3]